J. Randal Wexler of FutureCeuticals/Van Drunen Farms and Former Nature’s Bounty Exec Mitchell Slade Join Folium Biosciences Advisory Board
Colorado Springs, Colo. – November 24, 2020 – Hemp-derived non-psychoactive cannabinoid manufacturer Folium Biosciences welcomes J. Randal Wexler, Vice President and General Counsel of FutureCeuticals/Van Drunen Farms, and Nature’s Bounty Co. veteran Mitchell Slade to...One Year After Securing API License for Pharma Grade CBD, Folium Biosciences Reports Broad Global Pharmaceutical Adoption
Folium’s CBD API is an essential ingredient in pharmaceutical formulations worldwide. Colorado Springs, Colo. – October 15, 2020 – Since securing its Active Pharmaceutical Ingredient (API) license one year ago, Folium Biosciences’ CBD Isolate has been widely adopted...Global Veteran Specialty Ingredient Sales Executive Kris High Joins Folium Biosciences as Chief Commercialization Officer
After two decades of global sales leadership in the specialty food and ingredient sectors, Kris High has joined the executive team at hemp-derived non-psychoactive cannabinoid manufacturer Folium Biosciences as the company’s first Chief Commercialization Officer
Broad Spectrum Stalk CBD Oil
Folium Biosciences Introduces Broad Spectrum Stalk CBD Oil to Meet Global Demand from Stalk-and-Seed Countries Stalk-and-Seed Formulation Secures Approval for Distribution in Japan and South Korea. Folium Biosciences introduces Broad Spectrum Stalk...Tricia DiPersio, PhD, RD, Joins Folium Biosciences as EVP of Quality, Compliance & Customer Relations
Food, beverage and supplements industry veteran Tricia DiPersio, PhD, RD, has joined the executive team at Folium Biosciences as the company’s first EVP of Quality, Compliance and Customer Relations.